Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT02542293 |
Title | Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) (NEPTUNE) |
Acronym | NEPTUNE |
Recruitment | Active, not recruiting |
Gender | both |
Phase | Phase III |
Variant Requirements | Yes |
Sponsors | AstraZeneca |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA | TUR | SWE | ROU | POL | ISR | GRC | GBR | FIN | DNK | BRA | BGR | ARG |